Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation
| Autor: | Bin-Tao Huang, Bing-Sheng Li, Qingchun Zeng, Wei-Hong Zhao, Rui-lin Chen |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Treatment response Interferon α-2b Kaplan-Meier Estimate Interferon alpha-2 Gastroenterology Polycythemia vera Internal medicine medicine Humans Hydroxyurea Jak2v617f mutation Polycythemia Vera Aged business.industry Essential thrombocythemia Interferon-alpha Hematology Janus Kinase 2 Middle Aged medicine.disease Recombinant Proteins Hematologic Response Oncology Sustained response Mutation Mutation (genetic algorithm) Immunology Female business Thrombocythemia Essential |
| Zdroj: | Leukemia Research. 38:1177-1183 |
| ISSN: | 0145-2126 |
| DOI: | 10.1016/j.leukres.2014.06.019 |
| Popis: | This open-label, prospective, observational study aimed to evaluate treatment response, efficacy therapy and safety to IFN α-2b for the essential thrombocythemia (ET) and polycythemia vera (PV) with JAK2V617F positive mutation.A total of 123 ET patients received IFNα-2b therapy with JAK2V617F positive or negative mutation; and 136 PV patients with JAK2V617F(+) received IFNα-2b or hydroxyurea (HU) therapy according to random number assignment (ages 18-65 years old).ET patients receiving IFN α-2b with JAK2V617F(+) had a greater advantage in overall hematologic response (OHR) than JAK2V617F(-) (83.3% versus 61.4%, P0.01). For PV patients with JAK2V617F(+), IFN had no OHR superiority to HU (70.3% versus 70.8%, P0.05), but which gained a greater satisfactory molecular response than HU (54.7% versus 19.4%, P0.01). IFN significantly decreased the phlebotomy rate, which was better than HU for MPDs patients with OHR than HU (3.6% versus 65.7%, P0.01). Furthermore, ET patients with JAK2V617F(+) demonstrated a definite advantage over JAK2V617F(-) in five-year PFS (75.9% versus 47.6%, P0.05). For PV patients with JAK2V617F(+), IFN α-2b was superior to HU in five-year PFS (66.3% versus 46.7%, P0.01). Moreover, IFN α-2b also contributed to improved vasomotor symptoms in MPDs, and especially significantly decreased the incidence of distal paresthesias (14.1% versus 37.5%) and erythromelalgia (9.4% versus 29.2%) better than HU (P0.01). Meanwhile, IFN did not observe the severe hematological adverse events in patients with PV or ET.The data confirmed that IFN α-2b benefited the patients with ET or PV, particularly for JAK2V617F(+) mutation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect